Mikart LLC, a comprehensive contract development and manufacturing organization, has entered into a collaboration agreement with Fluid Pharma Ltd, a technology licensing company, to advance the application of Fluid Pharma’s  proprietary MicroCoat  technology in  new therapies for pediatric, geriatric, and oral liquid modified release applications, in North America.
 
Gus LaBella, director of Formulation Development at Mikart, commented, “MicroCoat technology will allow us to layer and coat smaller particles to incorporate into various dosage platforms thereby reducing grittiness and poor mouthfeel of these products. This will result in improved patient compliance and acceptability which can be a difficult problem especially with pediatric patients.”
 
Professor Fang Liu, founder of Fluid Pharma Ltd and inventor of the MicroCoat technology says, “We are extremely pleased to have entered into this technology partnership with Mikart, an industry recognized specialist manufacturer of multiparticulate systems such as pellets, micropellets and granules. By joining forces, Fluid and Mikart will be able to combine their technology, technical expertise, and manufacturing capabilities to bring MicroCoat to the market faster. We look forward to applying the MicroCoat technology in collaboration with our customers and partners in our effort to develop novel drugs with strong benefits to patients.”
 
Michael Kallelis, chief executive officer at Mikart, added, “This collaborative agreement with Fluid Pharma Ltd adds exciting, new capabilities to Mikart’s value-added multiparticulate coating services with the goal of improving patient-centricity of the oral drug products we develop and manufacture.”